DK2411027T3 - Anvendelse af et probiotikum til regulering af kropsvægt - Google Patents

Anvendelse af et probiotikum til regulering af kropsvægt Download PDF

Info

Publication number
DK2411027T3
DK2411027T3 DK10712041.2T DK10712041T DK2411027T3 DK 2411027 T3 DK2411027 T3 DK 2411027T3 DK 10712041 T DK10712041 T DK 10712041T DK 2411027 T3 DK2411027 T3 DK 2411027T3
Authority
DK
Denmark
Prior art keywords
glp
crl431
paracasei
expression
strain
Prior art date
Application number
DK10712041.2T
Other languages
English (en)
Inventor
Thomas Dyrmann Leser
Thomas Gunnarsson
Jens Kildsgaard
Janni Wandahl Pedersen
Benedicte Flambard
Original Assignee
Chr Hansen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chr Hansen As filed Critical Chr Hansen As
Application granted granted Critical
Publication of DK2411027T3 publication Critical patent/DK2411027T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

1. Sammensætning, som omfatter Lactobacillus paracasei subsp. Paracasei CRL431 med deponeringsnummer ATCC 55544 til anvendelse i forebyggelsen og/eller behandlingen af fedme.
2. Sammensætning, som omfatter Lactobacillus paracasei subsp. paracasei CRL431 med deponeringsnummer ATCC 55544 til anvendelse i forebyggelsen og/eller behandlingen af type 2-diabetes mellitus eller polycystisk ovariesyndrom (PCOS).
3. Sammensætning til anvendelse ifølge krav 1 eller 2, hvor Lactobacillus paracasei subsp. paracasei CRL431 med deponeringsnummer ATCC 55544 er kombineret med mindst ét prebiotikum.
4. Sammensætning til anvendelse ifølge krav 3, hvor det mindst ene prebiotikum er valgt fra gmppen bestående af: inulin, et transgalakto-oligosaccharid, palatinoseoligosaccharid, sojabønneoligosaccharid, gentiooligosaccharid, xylooligomerer, ikkenedbrydelig stivelse, lactosaccharose, lactulose, lactitol, maltitol, FOS (frukto-oligosaccharider), GOS (galakto-oligosaccharider) og polydextrose.
5. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor stammen Lactobacillus paracasei subsp. paracasei CRL431 med deponeringsnummer ATCC 55544 øger GLP-1-niveauet.
6. Kosmetisk fremgangsmåde til reduktion af kropsvægt hos en person, der ikke er fed eller overvægtig med et BMI (Body Mass Index) på mindre end 25, hvilken fremgangsmåde omfatter tilvejebringelse af en sammensætning, der omfatter Lactobacillus paracasei subsp. paracasei CRL431 med deponeringsnummer ATCC 55544.
7. Kosmetisk fremgangsmåde til reduktion af kropsvægt hos en person, der ikke er fed, hvilken fremgangsmåde omfatter tilvejebringelse af en sammensætning, der omfatter Lactobacillus paracasei subsp. paracasei CRL431 med deponeringsnummer ATCC 55544.
DK10712041.2T 2009-03-25 2010-03-24 Anvendelse af et probiotikum til regulering af kropsvægt DK2411027T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09156109 2009-03-25
PCT/EP2010/053826 WO2010108950A1 (en) 2009-03-25 2010-03-24 Use of a probiotic to regulate body weight

Publications (1)

Publication Number Publication Date
DK2411027T3 true DK2411027T3 (da) 2015-01-19

Family

ID=40921936

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10712041.2T DK2411027T3 (da) 2009-03-25 2010-03-24 Anvendelse af et probiotikum til regulering af kropsvægt

Country Status (7)

Country Link
US (2) US20120020944A1 (da)
EP (1) EP2411027B1 (da)
CN (1) CN102448477A (da)
DK (1) DK2411027T3 (da)
ES (1) ES2528602T3 (da)
PL (1) PL2411027T3 (da)
WO (1) WO2010108950A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506923A (ja) 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
FR3059678A1 (fr) * 2016-12-05 2018-06-08 Ecole Normale Superieure Lyon Bacteries lactiques utiles pour traiter les maladies metaboliques, notamment le diabete de type 2
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
US11938156B2 (en) * 2018-01-05 2024-03-26 Bened Biomedical Co., Ltd. Lactic acid bacteria and its applications
CN108813262A (zh) * 2018-07-02 2018-11-16 杭州相生相成科技有限公司 一种含dha藻油的复合益生菌固体饮料
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CN112007051B (zh) * 2019-05-28 2022-05-10 景岳生物科技股份有限公司 一种预防中风及改善中风严重度的组合物及其用途
CN115135749B (zh) * 2019-12-31 2025-02-18 Gi生物群系公司 植物乳杆菌菌株及含有其的用于预防或治疗代谢疾病的组合物
CN115135751B (zh) 2019-12-31 2025-02-18 Gi生物群系公司 发酵乳杆菌菌株及含有其的用于预防或治疗代谢疾病的组合物
CN114350547B (zh) * 2021-12-17 2023-05-16 四川省医学科学院·四川省人民医院 一种乳双歧杆菌菌株b-622及其在制备治疗糖尿病药物中的应用
CN115895973B (zh) * 2022-07-20 2023-11-17 南京农业大学 一株副干酪乳杆菌及其在白酸汤发酵制备中的应用
CN115975876B (zh) * 2022-11-30 2024-04-19 黑龙江八一农垦大学 一种预防雏鹅痛风的益生菌及其应用
WO2025102265A1 (en) * 2023-11-15 2025-05-22 Bened Biomedical Co., Ltd. Use of lacticaseibacillus bacteria for treating and/or preventing polycystic ovary syndrome
WO2025183428A1 (ko) * 2024-02-27 2025-09-04 (주)에이투젠 프로바이오틱스를 함유하는 남성 갱년기 증상의 개선용 조성물
CN119215078B (zh) * 2024-05-17 2026-03-03 北京大学 副干酪乳酪杆菌Lc19在降低血糖中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004124D0 (sv) 2000-11-10 2000-11-10 Probi Ab New use
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
PL1891436T3 (pl) * 2005-05-27 2013-02-28 Chr Hansen As Ilościowe określanie żywotności bakterii kwasu mlekowego z zastosowaniem cytometrii przepływowej
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
WO2007085970A2 (en) 2006-01-27 2007-08-02 Danisco A/S Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders

Also Published As

Publication number Publication date
ES2528602T3 (es) 2015-02-10
US20120020944A1 (en) 2012-01-26
CN102448477A (zh) 2012-05-09
EP2411027B1 (en) 2014-11-19
EP2411027A1 (en) 2012-02-01
WO2010108950A1 (en) 2010-09-30
US20130336942A1 (en) 2013-12-19
PL2411027T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
DK2411027T3 (da) Anvendelse af et probiotikum til regulering af kropsvægt
JP7595666B2 (ja) ラクトバチルス・プランタラム株、及びそれを含有する、代謝疾患を防止又は処置するための組成物
He et al. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics
A. Parnell et al. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome
JP7671285B2 (ja) ラクトバチルス・ファーメンタム株、及びそれを含有する、代謝疾患を防止又は処置するための組成物
US11571448B2 (en) Lactobacillus rhamnosus LM1019 strain and composition for preventing and treating obesity or diabetes mellitus comprising same
TWI572354B (zh) 抑制發炎之組成物
JP7671286B2 (ja) ラクトバチルス・ファーメンタム株、及びそれを含む、代謝疾患を防止又は処置するための組成物
US20120027737A1 (en) Use of probiotics to ameliorate diet-induced insulin resistance
WO2009153662A1 (en) New uses of lactic acid bacteria and bifidobacteria
TW202317162A (zh) 發酵乳酸桿菌菌株與自然殺手細胞用於組合療法以抑制體重增加以及預防或治療代謝疾病的用途
CN108451941A (zh) 治疗糖尿病的组合物和方法
CN102711800A (zh) 治疗糖尿病的组合物和方法
JP2025537795A (ja) リモシラクトバチルス・ムコサエ（Ｌｉｍｏｓｉｌａｃｔｏｂａｃｉｌｌｕｓ ｍｕｃｏｓａｅ）及びＧＬＰ－１増加を必要とする障害
Giralt et al. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat
US11285180B2 (en) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
HK1166256A (en) Use of a probiotic to regulate body weight
Park et al. Gut microbiota and obesity: focus on hormone regulation and appetite control
CA3164461C (en) Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases containing same
Wang et al. Combination of inulin and compound probiotic exert synergism in attenuating HFD-induced obesity but shows gender-difference
HK1166257A (en) Use of probiotics to ameliorate diet-induced insulin resistance
Tang et al. The therapeutic value of bifidobacteria in cardiovascular